April 18th 2024
A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.
Evinacumab (Evkeeza) Receives FDA Approval as Adjunct Therapy for HoFH
February 11th 2021A statement from Regeneron announced their ANGPTL3 inhibitor evinacumab (Evkeeza) received approval as an adjunct therapy for lowering LDL-C in patients 12 years and older with homozygous familial hypercholesterolemia.
Mayo Clinic Study Finds Definitive Link Between Omega-3 Intake and Cardiovascular Risk
September 18th 2020A meta-analysis of more than 3 dozen RCTs suggests increased intake of omega-3 supplements, such as EPA and DHA, was linked to a decreased risk of myocardial infarction action and coronary heart disease events.